Clinical Trial of Ilidar, a New Dibenzazepine Adrenergic Blocking Drug, in the Treatment of Peripheral Vascular Diseases and Miscellaneous Complaints | Zendy

Harold D. Green | Zendy; HUGH H. DUBOSE | Zendy

Open Access

Clinical Trial of Ilidar, a New Dibenzazepine Adrenergic Blocking Drug, in the Treatment of Peripheral Vascular Diseases and Miscellaneous Complaints

Author(s) -

Harold D. Green,

HUGH H. DUBOSE

Publication year - 1954

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.10.3.374

Subject(s) - medicine , drug , nausea , arteriosclerosis , peripheral , weakness , adrenergic , anesthesia , sympatholytics , pharmacology , surgery , receptor

Ilidar, a new adrenergic blocking drug, has been administered to 116 patients; follow-up was adequate on 86. The drug was highly effective in patients with predominantly vasospastic disorders and in patients with postphlebetic syndrome, and moderately effective in patients with thromboangiitis and arteriosclerosis. Most patients could tolerate 50 to 75 mg. three to four times a day. Side effects were principally those to be expected from the moderate postural hypotension associated with effective sympathetic blockade, namely, weakness, dizziness, nausea.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research